Roundtable Discussion: Evaluating the Need for Biomarker & Patient Selection Tools in an Increasingly Busy ADC Field
- Addressing the challenges and opportunities of biomarker analysis to select patient populations to benefit from specific ADCs
- Debating the most impactful time to commit to biomarker and patient selection approaches across translational and clinical ADC development
- How can we use predictive biomarkers to improve ADC patient selection; should we be looking beyond biomarkers of response to biomarkers of toxicity?